Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nelson Liou

Otolaryngology Houston, TX Medical Doctor

NPI 1518298587 CMS profile 1033061

6550 Fannin St, Ste 1727, Houston, TX 77030

Open in the dashboard

General payments

$18,326

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nelson Liou of Houston, TX is reported in the CMS Open Payments database as having received $18,326 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,453 19
2024 General $9,138 52
2023 General $995 13
2022 General $1,820 10
2021 General $728 8
2020 General $393 4
2019 General $3,799 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nelson Liou
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Nelson Liou were reported at $1,453. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Nelson Liou Otolaryngology median Middle half National median
2019 $3,799 $194 $82–$512 $163
2020 $393 $118 $42–$280 $114
2021 $728 $167 $63–$444 $132
2022 $1,820 $216 $84–$545 $149
2023 $995 $235 $93–$588 $160
2024 $9,138 $280 $111–$699 $164
2025 $1,453 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $5,374 25 payments
  2. Intersect ENT, Inc. $2,682 12 payments
  3. Inspire Medical Systems, Inc. $2,553 12 payments
  4. AxoGen $2,467 24 payments
  5. Aerin Medical Inc. $1,725 17 payments
  6. DePuy Synthes Sales Inc. $546 4 payments
  7. Stryker Corporation $470 3 payments
  8. Medtronic, Inc. $439 5 payments
  9. Acera Surgical, Inc. $374 2 payments
  10. Baxter Healthcare $321 3 payments
  11. Other $1,376 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,554 114 payments
  2. Education $4,000 2 payments
  3. Travel and Lodging $2,772 11 payments
Products named General payments · program years 2019–2025
  1. DA VINCI SP $4,000 2 payments
  2. PROPEL $2,682 12 payments
  3. SINUVA $2,192 6 payments
  4. AXOGUARD NERVE PROTECTOR $1,629 11 payments
  5. AxoGuard Nerve Connector $1,629 11 payments
  6. Da Vinci Surgical System $1,374 23 payments
  7. Inspire Upper Airway Stimulation System $1,345 4 payments
  8. RHINAER STYLUS $1,220 12 payments
  9. VIVAER STYLUS $1,220 12 payments
  10. INSPIRE $1,208 8 payments
  11. Other $4,573 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

181

Median for Otolaryngology: 297

Drug cost

$4,078

Median for Otolaryngology: $6,314

Branded share of claims

44.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine-Fluticasone Azelastine/Fluticasone Brand 17 $2,158
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 44 $801
Levothyroxine Sodium Generic 45 $343
Omeprazole Generic 28 $266
Fluticasone Propionate Generic 13 $187
Azelastine Hcl Generic 14 $171
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 20 $153

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$140,826

Medicare's payments for the services billed

Medicare patients

216

Average age 72

Services billed

474

94 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 41%
Ischemic heart disease 35%
Chronic kidney disease 28%
Depression 27%
COPD 25%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record